MNR
SPONSORED

Game-Changing Technology Revolutionizing the $188 Billion Connected Health Market(1) Has Created a Massive Opportunity for NASDAQ-Listed Biotricity Inc.

Is This Why Its Stock is Up About 1,078% in Just Over A Year?(2)

August 16, 2021
Biotricity reports 290% revenue growth year over year in record first quarter

The Top Reasons to Consider Biotricity U.S. NASDAQ: (BTCY) Right Now

  1. Biotricity may have game-changing technology that’s set to disrupt a massive $188 billion connected health market.(1)
  2. Biotricity’s Bioflux product has a total addressable market of about $1 billion and makes up nearly 100% of the company’s current revenue. In addition, “Bioflux is used by physicians who service 5% of the patient population — or a total of 2.2 million patients — which is approximately 2,000 patients per doctor among the 1,100 cardiologists who use the product.”(3)
  3. The company just reported that quarterly revenue increased 290% when comparing the first quarter of fiscal 2022 to the corresponding quarter of fiscal 2021. It’s also seen continued acceleration over the 227% growth in Q4/2021, 162% growth in Q3/2021, and 115% growth in Q2/2021.(4)

The healthcare system is broken.

It’s fragmented, frustrating, and poorly coordinated. Healthcare workers are understandably exhausted. Hospitals are teetering on the edge of being overwhelmed.

According to a report from the Society of Actuaries:

“These deficiencies are particularly troubling for people with chronic conditions who, on average, use the health care system more frequently, consume more health care resources, and are more likely to see multiple health care professionals and have long-term relationships with them. When the health care system fails, chronically ill patients are often harmed the most. The foremost reason America’s health care system cannot optimally provide the services needed by people with chronic conditions.”(5)

Most of us have seen it with our own eyes.

So, where do we go from here? How do we fix the chaos?

At the moment, according to Benzinga, “51.7% of U.S. adults suffer from a chronic disease. In fact, 7 of the top 10 chronic diseases are among the top 10 causes of death in the U.S., and 86% of healthcare dollars is spent on chronic diseases.”(6)

Making matters worse, current outdated, non-connected technology is subject to higher rates of error. Also, it frequently can take a month before data is collected, they added.(6)

With soaring rates of chronic disease overwhelming the healthcare system, the opportunity is ripe for new technology enabling physicians to diagnose and monitor patients with chronic conditions. That’s why NASDAQ-listed Biotricity U.S. NASDAQ: (BTCY) may have earth-shaking promise. Biotricity, a cutting-edge medical technology company, is fully committed to improving healthcare by developing chronic disease prevention and management solutions.

Since December 2019, Biotricity’s U.S. NASDAQ: (BTCY) Stock Has Soared Roughly 1,047%(2)

This may be one of the most revolutionary companies set to disrupt a massive $188 billion connected health market (Source 1) with its game-changing technology.

Even more impressive is its chart over the last year and a half.

After bottoming out around 27 cents in late December 2019, the stock exploded to a closing price of $3.18 as of September 13, 2021 – good for a stunning move of approximately 1,078%.

In addition, as of September 13, 2021, many of its short-, medium-, and long-term indicators look bullish, too, including its 20-100 day MACD oscillator, 20-200 day MACD oscillator, 50-100 day MACD oscillator, 50-150 day MACD oscillator, 50-200 day MACD oscillator, 100-day MA, 150-day MA, 200-day MA, and 100-200 day MACD oscillator.(7)

This only scratches the surface of BTCY’s breakneck growth, though. Biotricity’s U.S. NASDAQ: (BTCY) earnings growth is off the medical charts.

The company is seeing jaw-dropping growth.

For Q1 Fiscal 2022, Biotricity reported:(4)

  • Q1 revenue of $1.76 million – now the 9th consecutive quarter of triple-digit YoY growth.
  • Quarterly revenue increased 290% when comparing the first quarter of fiscal 2022 to the corresponding quarter of fiscal 2021, showing continued acceleration over the 227% growth in Q4/2021, 162% growth in Q3/2021, and 115% growth in Q2/2021.
  • Quarterly sequential revenue increased 49% compared to 19% posted in the prior quarter, a significant acceleration bolstered by consistent month-over-month sequential growth.
  • Nearly tripled sales with a more minor corresponding increase in Operating Expenses, which rose only 17% to $4.2 million for Q1 FY22 compared to $3.6 million in the prior year.

Based on current trends, the company is projecting continued revenue growth for fiscal 2022 and into fiscal 2023. As a reminder, Biotricity filed a 510(K) seeking FDA approval for its new Biotres holter product on December 31, 2020. It is fully prepared for a fast launch following that approval. Although the approval process has been slowed somewhat by the widely reported FDA backlog, the process is otherwise on track in terms of required steps.

Why So Much Excitement About NASDAQ-Listed Biotricity Inc. U.S. NASDAQ: (BTCY)?

NASDAQ-listed Biotricity’s U.S. NASDAQ: (BTCY) lead product is Bioflux. This integrated mobile cardiac telemetry solution consists of a proprietary mobile ECG monitoring device and an ECG viewer software package.

With it, physicians can remotely monitor and diagnose patients with cardiovascular coronary heart disease by detecting probable arrhythmias, along with other diagnostic heart information.

Even better, according to Benzinga:

Bioflux has a total addressable market of about $1 billion and makes up almost 100% of the company’s current revenue. Plus, “Bioflux is used by physicians who service 5% of the patient population — or a total of 2.2 million patients — which is approximately 2,000 patients per doctor among the 1,100 cardiologists who use the product.”(3)

Here’s how it works.

However, there’s far more to get excited about.

Biotricity Inc. U.S. NASDAQ: (BTCY) Is Also Entering The Flourishing Telemedicine Space

Telemedicine was already a growing sector long before the health scare. However, the world has now woken up to its benefits, and the industry is seeing significant momentum.

Fortune Business Insights forecasts the Global Telemedicine Market to witness an estimated 23.5% CAGR through 2026 and hit an approximately $185,669.6 million valuation.(9)

That’s only one of the many reasons why Biotricity’s foray into telemedicine appears to be so promising.

Biotricity’s “Biocare Telemed” could be the future of physician and patient consultations. This platform functions as a virtual health clinic with secure HIPPA compliant technology.(10)

The platform can also potentially enable clinicians to provide outstanding patient care remotely. All while ensuring at-risk patients and those needing remote cardiac monitoring do not have to leave the safety of their homes.

Biotricity Inc. U.S. NASDAQ: (BTCY) Is Launching Bioheart

Bioheart records your electrical heart activity continuously while you wear it, giving you reliable, 24/7 data to deliver the most accurate insights on your heart. Bioheart is suitable for everyday use and compatible with any lifestyle and activity level. Bioheart precisely captures your heart rhythm during strenuous exercise like running or cardio or as you go about your daily routine.(11)

Biotricity Inc. U.S. NASDAQ: (BTCY) Also Now Has an App To Manage Pain

Biotricity also provides patients with an interactive app called “Biocare Pain Management,” helping patients and physicians manage pain through logging and tracking.(12)

Biotricity U.S. NASDAQ: (BTCY) is Led by a Healthy Team with Years of Experience

Dr. Waqaas Al-Siddiq, PhD
Chairman, CEO & Founder

Waqaas, the founder of Biotricity, is a serial entrepreneur, a former investment advisor, and an expert in wireless communication technology. Academically, he was distinguished for his various innovative designs in digital, analog, embedded, and micro-electro-mechanical products. His work was published in multiple conferences such as IEEE and the National Communication Council.

Waqaas has held several high-level design positions in IBM, AMD, and Intel. His achievements have been numerous in both the technological and academic world. Coupled with this, Waqaas has vast experience leading various groups through his board experience and executive roles within start-ups, mid-sized companies, and nonprofits.

Norman Betts, PhD
Independent Board Member

Norman sits on the Boards of Directors of the Bank of Canada, Tembec Inc., New Brunswick Power Corporation, 49 North Resources Inc., Adex Mining Inc., Tanzanian Royalty Exploration Inc., and the University of New Brunswick Pension Plan for Academic Employees.

Norman is an Associate Professor in the Faculty of Business Administration at the University of New Brunswick in Fredericton. He is accomplished in accounting and finance, with a mix of academic, public, and private-sector experience. Norman received a Ph.D. in Management with a concentration in accounting and finance from Queen’s University School of Business in 1992 and a Bachelor of Business Administration from the University of New Brunswick in 1978. He also holds a Fellow Chartered Accountant designation.

Dave Rosa
Independent Board Member

Dave has spent the past 22 years in a variety of positions in the medical device industry. He was appointed CEO of Sunshine Heart in October of 2009 and served as President and Chief Executive Officer through November 2015. Dave took Sunshine Heart Public on NASDAQ in 2012 and raised over $120M during his tenure. The Company achieved several clinical, regulatory, and R&D milestones under his leadership. Before joining Sunshine Heart, he was President and CEO of Milksmart, Inc., a privately held company developing a unique stent-like agricultural technology that increases milking efficiencies, output, and quality.

Patricia Kennedy
Independent Board Member

Patricia has spent over 25 years in a variety of global sales and distribution positions in the medical device industry, focusing on Electrophysiology. In 2015, she founded and is currently the Managing Director of PJM Medical Consultants. This company supports medical device companies entering the international market with market entry and product commercialization strategies. From 2008 to 2015, Pat served as VP – International and General Manager for Atricure, Inc. She achieved significant sales, market development, and clinical science milestones while defining strategic plans and pursuing technology development and acquisitions. From 2001 to 2008, Pat worked with Stereotaxis, Inc. in numerous executive positions, including Worldwide VP – Clinical Services and VP – International Sales and Marketing.

Steve Salmon
Independent Board Member

Steve Salmon has expertise in business development transactions, market development, finance, technology, and capital market. His most recent experience was as a Venture Capitalist for Latterell Venture Partners where he managed several portfolio companies. Before becoming a VC, Mr. Salmon was a founder of Ensure Medical and Integrated Vascular Systems, both of which were successfully exited through acquisition. He also served as the CEO of Revascular, which was also acquired. Mr. Salmon brings to Biotricity his deep expertise in raising capital, facilitating growth, and driving long-term value.

John Ayanoglou
Chief Financial Officer

John has over 25 years of accounting, finance, and operations experience, having previously served as CFO of several public companies and a regulated financial institution. As CFO of Equitable Group, Mr. Ayanoglou raised over $130 million of regulatory capital in common, preferred, and debenture offerings over successive transactions. All of this was done during a period of extreme capital market turbulence. He successfully grew assets under administration from $6.1 billion to over $10 billion to facilitate Equitable Bank in becoming Canada’s ninth-largest bank. He was also the CFO and Corporate Secretary of Xceed Mortgage Corporation. There, he partnered with a top entrepreneurial team to grow the business by successfully implementing warehouse financing lines and other securitization programs, including public term securitizations of over $700 million.

Amir Ali
Chief Development Officer

Amir is a serial entrepreneur with over 20 years of experience launching companies and producing innovative products, services, and solutions. Amir is sought after for his expertise in transforming R&D technologies into products based on market needs, commercializing products for volume production, and establishing global distribution channels.

Spencer LaDow
Vice President, Engineering

Spencer is an expert in wireless communication and has worked with the United States Department of Defense. His academic career was highlighted by various innovative projects and designs. Spencer obtained his undergraduate degree while balancing a full-time job at Flightline Systems Ultra Electronics, a small defense contractor. His specialties are in designing and implementing radio frequency, digital, analog, embedded software, and PC software. Spencer also has experience working with marketing, sales, and manufacturing teams to develop products for large-scale output.

The Top Reasons to Consider Biotricity U.S. NASDAQ: (BTCY) Right Now

  1. Biotricity may have game-changing technology that’s set to disrupt a massive $188 billion connected health market.(1)
  2. Biotricity’s Bioflux product has a total addressable market of about $1 billion and makes up nearly 100% of the company’s current revenue. In addition, “Bioflux is used by physicians who service 5% of the patient population — or a total of 2.2 million patients — which is approximately 2,000 patients per doctor among the 1,100 cardiologists who use the product.”(3)
  3. The company just reported that quarterly revenue increased 290% when comparing the first quarter of fiscal 2022 to the corresponding quarter of fiscal 2021. It’s also seen continued acceleration over the 227% growth in Q4/2021, 162% growth in Q3/2021, and 115% growth in Q2/2021.(4)

Source 1: https://www.globenewswire.com/news-release/2020/01/03/1966006/0/en/Global-IoT-in-Healthcare-Market-Set-to-Reach-188-Billion-by-2024-Exhibiting-a-CAGR-of-27-6-from-2019.html
Source 2: https://stockcharts.com/h-sc/ui?s=btcy
Source 3: https://markets.businessinsider.com/news/stocks/improving-cardiac-conditions-through-disruptive-medical-technologies-1030567214
Source 4: https://www.accesswire.com/660014/Biotricity-Reports-290-Revenue-Growth-Year-Over-Year-in-Record-First-Quarter
Source 5: https://www.soa.org/globalassets/assets/files/resources/essays-monographs/financing-chronic-care/m-hb05-1_vi.pdf
Source 6: https://www.benzinga.com/general/biotech/21/06/21786883/improving-cardiac-conditions-through-disruptive-medical-technologies
Source 7: https://www.barchart.com/stocks/quotes/BTCY/opinion
Source 8: https://www.biotricity.com/bioflux-2/
Source 9: https://www.globenewswire.com/en/news-release/2020/12/07/2140336/0/en/Global-Telemedicine-Market-Size-to-Reach-USD-185-669-6-Million-by-2026-InTouch-Health-Launches-an-End-to-end-Platform-Solo-to-Help-Users-Worldwide-Fortune-Business-Insights.html
Source 10: https://www.biotricity.com/biocare-telemed/
Source 11: https://www.biotricity.com/bioheart/

Legal Disclaimer


This website / media webpage is owned, operated and edited by TD Media LLC. Any wording found on this website / media webpage or disclaimer referencing to “I” or “we” or “our” or “TD Media” refers to TD Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage.We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. TD Media business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, TD Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.

INFLUENCER COMPENSATION

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 02/16/2021 and ending on 02/18/2021 to publicly disseminate information about (BTCY:US) via digital communications. We have paid this Influencer three hundred fifty dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 02/17/2021 and ending on 02/19/2021 to publicly disseminate information about (BTCY:US) via digital communications. We have paid this Influencer one hundred dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 02/17/2021 and ending on 02/17/2021 to publicly disseminate information about (BTCY:US) via digital communications. We have paid this Influencer eight hundred dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 02/17/2021 and ending on 02/17/2021 to publicly disseminate information about (BTCY:US) via digital communications. We have paid this Influencer one thousand five hundred dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 02/17/2021 and ending on 02/19/2021 to publicly disseminate information about (BTCY:US) via digital communications. We have paid this Influencer seven hundred dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 02/18/2021 and ending on 02/18/2021 to publicly disseminate information about (BTCY:US) via digital communications. We have paid this Influencer one thousand five hundred forty five dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 02/18/2021 and ending on 02/18/2021 to publicly disseminate information about (BTCY:US) via digital communications. We have paid this Influencer six hundred dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 02/19/2021 and ending on 02/19/2021 to publicly disseminate information about (BTCY:US) via digital communications. We have paid this Influencer eight hundred dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 02/22/2021 and ending on 02/22/2021 to publicly disseminate information about (BTCY:US) via digital communications. We have paid this Influencer one thousand dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 02/24/2021 and ending on 02/24/2021 to publicly disseminate information about (BTCY:US) via digital communications. We have paid this Influencer nine hundred dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 02/25/2021 and ending on 02/25/2021 to publicly disseminate information about (BTCY:US) via digital communications. We have paid this Influencer one thousand dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 06/02/2021 and ending on 06/04/2021 to publicly disseminate information about (BTCY:US) via digital communications. We have paid this Influencer five hundred dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 09/08/2021 and ending on 09/10/2021 to publicly disseminate information about (BTCY:US) via digital communications. We have paid this Influencer seven hundred dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 09/08/2021 and ending on 09/10/2021 to publicly disseminate information about (BTCY:US) via digital communications. We have paid this Influencer one thousand dollars USD.

Pursuant to an agreement between TD Media LLC and Influencer, TD Media LLC has hired Influencer for a period beginning on 09/08/2021 and ending on 09/10/2021 to publicly disseminate information about (BTCY:US) via digital communications. We have paid this Influencer seven hundred dollars USD.

INTERVIEW COMPENSATION

Pursuant to an agreement between TD Media LLC and Interviewer, TD Media LLC has hired Interviewer for a period beginning on 03/02/2021 and ending on 03/02/2021 to publicly disseminate information about (BTCY:US) via digital communications. We have paid this Interviewer two thousand three hundred dollars USD.

RADIO COMPENSATION

Pursuant to an agreement between TD Media LLC and a Radio broadcast agency, TD Media LLC has hired a Radio broadcast agency for a period beginning on 02/22/2021 and ending on 02/26/2021 to publicly disseminate information about (BTCY:US) via digital communications. We have paid this a Radio broadcast agency five thousand dollars USD.

Pursuant to an agreement between TD Media LLC and a Radio broadcast agency, TD Media LLC has hired a Radio broadcast agency for a period beginning on 03/01/2021 and ending on 03/05/2021 to publicly disseminate information about (BTCY:US) via digital communications. We have paid this a Radio broadcast agency five thousand dollars USD.

Pursuant to an agreement between TD Media LLC and a Radio broadcast agency, TD Media LLC has hired a Radio broadcast agency for a period beginning on 03/08/2021 and ending on 03/12/2021 to publicly disseminate information about (BTCY:US) via digital communications. We have paid this a Radio broadcast agency five thousand dollars USD.

COMPENSATION

Pursuant to an agreement between TD Media LLC and Biotricity Inc, TD Media LLC has been hired for a period beginning on 02/12/2021 and ending on 02/25/2021 to publicly disseminate information about (BTCY:US) via digital communications. We have been paid fifty thousand dollars USD via bank wire transfer.

Pursuant to an agreement between TD Media LLC and Biotricity Inc, TD Media LLC has been hired for a period beginning on 02/26/2021 and ending on 03/11/2021 to publicly disseminate information about (BTCY:US) via digital communications. We have been paid an additional fifty thousand dollars USD via bank wire transfer. We own zero shares of (BTCY:US). To date we have been paid one hundred thousand dollars USD via bank wire transfer. To disseminate information about (BTCY:US) via digital communications.

Pursuant to an agreement between TD Media LLC and Biotricity Inc, TD Media LLC has been hired for a period beginning on 03/15/2021 and ending on 03/26/2021 to publicly disseminate information about (BTCY:US) via digital communications. We have been paid an additional fifty thousand dollars USD via bank wire transfer. We own zero shares of (BTCY:US). To date we have been paid one hundred fifty thousand dollars USD via bank wire transfer. To disseminate information about (BTCY:US) via digital communications.

Pursuant to an agreement between TD Media LLC and Biotricity Inc, TD Media LLC has been hired for a period beginning on 03/29/2021 and ending on 04/09/2021 to publicly disseminate information about (BTCY:US) via digital communications. We have been paid an additional fifty thousand dollars USD via bank wire transfer. We own zero shares of (BTCY:US). To date we have been paid two hundred thousand dollars USD via bank wire transfer. To disseminate information about (BTCY:US) via digital communications.

Pursuant to an agreement between TD Media LLC and Biotricity Inc, TD Media LLC has been hired for a period beginning on 03/29/2021 and ending on 04/09/2021 to publicly disseminate information about (BTCY:US) via digital communications. We have been paid an fifty thousand dollars USD via bank wire transfer. Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 05/26/2021 and ending on 06/09/2021 to publicly disseminate information about (BTCY:US) via digital communications. We have been paid an additional twenty five thousand dollars USD via bank wire transfer. We own zero shares of (BTCY:US). To date we have been paid two hundred twenty five thousand dollars USD via bank wire transfer. To disseminate information about (BTCY:US) via digital communications.

Pursuant to an agreement between TD Media LLC and Biotricity Inc, TD Media LLC has been hired for a period beginning on 03/29/2021 and ending on 04/09/2021 to publicly disseminate information about (BTCY:US) via digital communications. We have been paid an fifty thousand dollars USD via bank wire transfer. Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 09/07/2021 and ending on 09/13/2021 to publicly disseminate information about (BTCY:US) via digital communications. We have been paid an additional twenty three thousand dollars USD via bank wire transfer. We own zero shares of (BTCY:US). To date we have been paid two hundred forty eight thousand dollars USD via bank wire transfer. To disseminate information about (BTCY:US) via digital communications.

Pursuant to an agreement between TD Media LLC and Biotricity Inc, TD Media LLC has been hired for a period beginning on 03/29/2021 and ending on 04/09/2021 to publicly disseminate information about (BTCY:US) via digital communications. We have been paid an fifty thousand dollars USD via bank wire transfer. Pursuant to an agreement between TD Media LLC and Legends Media LLC, TD Media LLC has been hired for a period beginning on 09/15/2021 and ending on 09/17/2021 to publicly disseminate information about (BTCY:US) via digital communications. We have been paid an additional ten thousand dollars USD via bank wire transfer. We own zero shares of (BTCY:US). To date we have been paid two hundred fifty eight thousand dollars USD via bank wire transfer. To disseminate information about (BTCY:US) via digital communications.

NASDAQ:BTCY
Company Contact

Address: 275 Shoreline Drive Suite 150 Redwood City CA 94065 US
Phone: +1 650 832-1626
Website: https://www.biotricity.com
Email: [email protected]

What They Do

Biotricity Inc is a medical technology company. The company is focused on biometric data monitoring solutions. Its aim is to deliver remote monitoring solutions to the medical, healthcare, and consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. Biotricity is expanding medical-grade monitoring into the consumer market via its Biolife solution, which empowers users to self-manage chronic conditions. Biolife helps users make lifestyle changes by combining medically relevant ECG data with social media interactivity and a lifestyle blog.